From Inc · · 1m 20s
Eli Lilly Cracking Down on Weight-Loss Drug in Georgia Clinics
Eli Lilly is shutting down Georgia clinics promoting unapproved weight-loss drug retatrutide.
In brief
Eli Lilly is shutting down Georgia clinics promoting unapproved weight-loss drug retatrutide. Eli Lilly has stopped Georgia clinics from selling unapproved weight-loss drug retatrutide despite ongoing clinical trials. Originally reported by Inc.
Eli Lilly's Crackdown
Eli Lilly is cracking down on Georgia clinics promoting unapproved weight-loss drug retatrutide.
“Anything sold to consumers outside of those trials is illegal, with no way to verify its safety, purity or dosing”
At Least 17 Clinics Promote Drug
At least 17 medical facilities in Georgia have advertised or promoted retatrutide, an investigational drug by Eli Lilly.
Drug Still in Development
Retatrutide is a once-weekly injectable drug that activates receptors for three hormones: GLP-1, GIP, and glucagon.
Eli Lilly's Stance
Eli Lilly says retatrutide is legally available only through clinical trials and anything sold outside is illegal.
“Anything sold to consumers outside of those trials is illegal, with no way to verify its safety, purity or dosing”
Drug Not FDA Approved
Retatrutide has not been approved by the Food and Drug Administration and is still being studied by Eli Lilly.
Growing Demand for Weight Loss
About one in eight U.S. adults reported taking a GLP-1 drug for weight loss or another health condition in late 2.025.
Clinical Trials for Multiple Conditions
Eli Lilly is studying retatrutide for obesity, type 2 diabetes, obstructive sleep apnea, and knee osteoarthritis pain.
Safety and Effectiveness Under Evaluation
The safety and effectiveness of retatrutide remain under evaluation by Eli Lilly.
The bottom line
Eli Lilly has stopped Georgia clinics from selling unapproved weight-loss drug retatrutide despite ongoing clinical trials.
